Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular...

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Lipid Metabolism

Background:

• Conventional low-density lipoprotein cholesterol (LDL-C) assays inaccurately measure cholesterol, as they include cholesterol from both LDL and lipoprotein(a) particles.
• This methodological limitation can impact clinical care and cardiovascular disease (CVD) risk assessment.

Purpose of the Study:

• To compare the associations of standard LDL-C and corrected LDL-C (LDL-C_corr30) with CVD risk.
• To evaluate the effect of LDL-C correction on patient classification into guideline-recommended LDL-C categories.

Main Methods:

• Lipoprotein(a) cholesterol was estimated as 30% of its mass and subtracted from LDL-C to derive LDL-C_corr30.
• Individual patient data from 5 statin landmark trials (18,043 patients) were used for meta-analysis to quantify CVD hazard ratios.
• Reclassification of patients was assessed using a large laboratory database (531,144 patients).

Main Results:

• Standard LDL-C, but not LDL-C_corr30, was significantly associated with increased CVD risk (HR 1.17 vs. 1.07).
• Using LDL-C_corr30 led to significant reassignment of patients to lower LDL-C categories across various baseline LDL-C ranges.
• Proportions reassigned ranged from 30.2% to 41.1% depending on the initial LDL-C category.

Conclusions:

• Standard LDL-C measurement is associated with incident CVD primarily due to the inclusion of lipoprotein(a) cholesterol.
• Accurate LDL-C measurement, especially in patients with elevated lipoprotein(a), is crucial for precise cardiovascular risk assignment.
• Refined measurement techniques are needed to attribute risk correctly to specific lipoproteins.